|
|
June Li, Daniel P. Sejas, Xiaoling Zhang, Yuhui Qiu, Kalpana J. Nattamai, Reena Rani, Keaney R. Rathbun, Hartmut Geiger, David A. Williams, Grover C. Bagby, Qishen Pang
J Clin Invest. 2007;
117(11):3283
doi:10.1172/JCI31772
Abstract |
Full text
| PDF
| Supplemental material

T
he molecular pathogenesis of the myeloid leukemias that frequently occur in patients with Fanconi anemia (FA) is not well defined. Hematopoietic stem cells bearing inactivating mutations of FA complementation group C (FANCC) are genetically unstable and hypersensitive to apoptotic cytokine cues including IFN-γ and TNF-α, but neoplastic stem cell clones that arise frequently in vivo are resistant to these cytokines. Reasoning that the combination of genetic instability and cytokine hypersensitivity might create an environment supporting the emergence of leukemic stem cells, we tested the leukemia-promoting effects of TNF-α in murine stem cells. TNF-α exposure initially profoundly inhibited the growth of Fancc–/– stem cells. However, longer-term exposure of these cells promoted the outgrowth of cytogenetically abnormal clones that, upon transplantation into congenic WT mice, led to acute myelogenous leukemia. TNF-α induced ROS-dependent genetic instability in Fancc–/– but not in WT cells. The leukemic clones were TNF-α resistant but retained their characteristic hypersensitivity to mitomycin C and exhibited high levels of chromosomal instability. Expression of FANCC cDNA in Fancc–/– stem cells protected them from TNF-α–induced clonal evolution. We conclude that TNF-α exposure creates an environment in which somatically mutated preleukemic stem cell clones are selected and from which unaltered TNF-α–hypersensitive Fancc–/– stem cells are purged.
Citation information
This citation data is accumulated from CrossRef, which receives citation information from participating publishers, including this journal.
Not all publishers participate in CrossRef, so this information is not comprehensive.
Additionally, data may not reflect the most current citations to this article,
and the data may differ from citation information available from other sources
(for example, Google Scholar, Web of Science, and Scopus).
Total citations by year
in CrossRef
Citations to this article
in CrossRef
(27)
| Title and authors |
Publication |
Year |
Down-regulated expression of hsa-miR-181c in Fanconi anemia patients: implications in TNF regulation and proliferation of hematopoietic progenitor cells
P. Rio, X. Agirre, L. Garate, R. Banos, L. Alvarez, E. San Jose-Eneriz, I. Badell, J. A. Casado, M. Garin, F. Prosper
|
Blood
|
2012 |
Current and emerging therapeutic strategies for Fanconi anemia
Pallavi Shukla, Kanjaksha Ghosh, Babu R Vundinti
|
HUGO J
|
2012 |
Myelodysplasia and leukemia of Fanconi anemia are associated with a specific pattern of genomic abnormalities that includes cryptic RUNX1/AML1 lesions
S. Quentin, W. Cuccuini, R. Ceccaldi, O. Nibourel, C. Pondarre, M.-P. Pages, N. Vasquez, C. Dubois d'Enghien, J. Larghero, R. Peffault de Latour, V. Rocha, J.-H. Dalle, P. Schneider, M. Michallet, G. Michel, A. Baruchel, F. Sigaux, E. Gluckman, T. Leblanc, D. Stoppa-Lyonnet, C. Preudhomme, G. Socie, J. Soulier
|
Blood
|
2011 |
TNF alpha antagonist therapy and safety monitoring
Thao Pham, Hervé Bachelez, Jean-Marie Berthelot, Jacques Blacher, Yoram Bouhnik, Pascal Claudepierre, Arnaud Constantin, Bruno Fautrel, Philippe Gaudin, Vincent Goëb, Laure Gossec, Philippe Goupille, Séverine Guillaume-Czitrom, Eric Hachulla, Isabelle Huet, Denis Jullien, Odile Launay, Marc Lemann, Jean-Francis Maillefert, Jean-Pierre Marolleau, Valérie Martinez, Charles Masson, Jacques Morel, Luc Mouthon, Stanislas Pol, Xavier Puéchal, Pascal Richette, Alain Saraux, Thierry Schaeverbeke, Martin Soubrier, Anne Sudre, Tu-Anh Tran, Manuelle Viguier, Olivier Vittecoq, Daniel Wendling, Xavier Mariette, Jean Sibilia
|
Joint Bone Spine
|
2011 |
Methods in Cell Biology
Adriana Rodríguez-Marí, John H. Postlethwait
|
Methods in Cell Biology Volume 105
|
2011 |
TNF facilitates clonal expansion of JAK2V617F positive cells in myeloproliferative neoplasms
A. G. Fleischman, K. J. Aichberger, S. B. Luty, T. G. Bumm, C. L. Petersen, S. Doratotaj, K. B. Vasudevan, D. H. LaTocha, F. Yang, R. D. Press
|
Blood
|
2011 |
Fanconi Anemia
J. Soulier
|
Hematology
|
2011 |
Spontaneous abrogation of the G2 DNA damage checkpoint has clinical benefits but promotes leukemogenesis in Fanconi anemia patients
Raphael Ceccaldi, Delphine Briot, Jérôme Larghero, Nadia Vasquez, Catherine Dubois d’Enghien, Delphine Chamousset, Maria-Elena Noguera, Quinten Waisfisz, Olivier Hermine, Corinne Pondarre, Thierry Leblanc, Eliane Gluckman, Hans Joenje, Dominique Stoppa-Lyonnet, Gérard Socié, Jean Soulier
|
J. Clin. Invest.
|
2010 |
Fancd2-/- mice have hematopoietic defects that can be partially corrected by resveratrol
Q.-S. Zhang, L. Marquez-Loza, L. Eaton, A. W. Duncan, D. C. Goldman, P. Anur, K. Watanabe-Smith, R. K. Rathbun, W. H. Fleming, G. C. Bagby, M. Grompe
|
Blood
|
2010 |
Cross talk between stimulated NF-κB and the tumor suppressor p53
G Schneider, A Henrich, G Greiner, V Wolf, A Lovas, M Wieczorek, T Wagner, S Reichardt, A von Werder, R M Schmid, F Weih, T Heinzel, D Saur, O H Krämer
|
Oncogene
|
2010 |
|